Furthermore, CgA seems to not be a reliable indicator of recurrences, and a false increase in this biomarker can be common in the context of atrophic gastritis or after proton pump inhibitor treatment and renal and liver diseases [22,23]. This evidence concerns the gene CGA and liver disorder.